Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

amyloidosis cutis dyschromia - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

amyloidosis cutis dyschromia

MONDO:0017906

Also known as:amyloidosis cutis dyschromica

Overview

Amyloidosis cutis dyschromia is a rare primary cutaneous amyloidosis characterized by macular or reticulate hyperpigmentation with symmetrically distributed guttate hypo- and hyperpigmented lesions which progress gradually over the years to involve almost the entire body (with relative sparing of the face, hands, feet and neck). Patients are usually asymptomatic, however mild pruritus may be associated. Amyloid deposition in the papillary dermis is observed on skin biopsy. Systemic amyloidosis is not present and association with generalized morphea, atypical Parkinsonism, spasticity, motor weakness or colon carcinoma is rare.

ResearchLimited published research (7 articles)

Prognosis

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for amyloidosis cutis dyschromia.

7 publications have been identified in PubMed for amyloidosis cutis dyschromia. Research spans Case Report / Case Series (71%) and Other (29%).

Recent Publications

Vasilevsky NA (2026). [PMID: 41052288](https://pubmed.ncbi.nlm.nih.gov/41052288/). *Genetics*. [Other]
Zhong CJ (2025). [PMID: 39487057](https://pubmed.ncbi.nlm.nih.gov/39487057/). *An Bras Dermatol*. [Case Report / Case Series]
Korany MM (2025). [PMID: 39912137](https://pubmed.ncbi.nlm.nih.gov/39912137/). *Indian J Dermatol Venereol Leprol*. [Other]
Untaaveesup S (2025). [PMID: 40792575](https://pubmed.ncbi.nlm.nih.gov/40792575/). *Acta Derm Venereol*. [Case Report / Case Series]
Priyadhashini BV (2024). [PMID: 39119318](https://pubmed.ncbi.nlm.nih.gov/39119318/). *Indian J Dermatol*. [Case Report / Case Series]
Rane MC (2024). [PMID: 39119323](https://pubmed.ncbi.nlm.nih.gov/39119323/). *Indian J Dermatol*. [Case Report / Case Series]

Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:56 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:319635

GARD

Genetic and Rare Diseases Info Center

GARD:17466

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

amyloidosis cutis dyschromia

Overview

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team